Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The new vaccine committee appointed by Secretary Robert F. Kennedy Jr. took minimal action in its first meeting.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Two young elephants at the Zoo, Sanjay and Kabir, overcame a deadly virus thanks to a new vaccine introduced to zoos ...

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...